Citeline Podcasts

Pennine Health Talks Sustainability Compliance and ESG Initiatives by Citeline

Pink Sheet reporter and editors discuss a new pilot project allowing collaborative reviews of gene therapies by multiple regulators (:42), predictions for the upcoming year by current and former US FDA leaders (11:12), and the FDA commissioner’s take on artificial intelligence (21:23). More On These Topics From The Pink Sheet Don’t Call It Project Orbis: CoGenT Global Will Pilot Collaborative Revi...

In the latest episode of the In Vivo podcast, non-executive chair Peter Bains and Owain Millington, vice president of immunology and head of preclinical, discuss ILC Therapeutics’ platform technology, financing plans as well as the pros and cons of running a startup biotech in the UK.

Join Jung Won Shin for this Korean-language mini podcast talking about a report from Citeline's Datamonitor Healthcare. Datamonitor Healthcare의 비만치료제시장 분석리포트를 요약한 내용입니다. https://www.biomedtracker.com/reportdetail.cfm?reportid=863

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: 2023 drug launch highlights; the M&A outlook for the new year; AstraZeneca’s China cell therapy acquisition; the pre-Christmas deal flow; and India at a turning point for ADCs? https://scrip.citeline.com/SC149606/Quick-Listen-Scrips-Five-MustKnow-Things

Listen as Chris Smyth, President, ICON Biotech Solutions discusses current trends in the biotech landscape, and predictions for future innovation, regulation and globalisation in this space. Recorded on Wednesday 15th November.

One week into 2024, there have already been multiple deals between Chinese innovative drug developers and multinational and the significant acquisition of GracellBio by AstraZeneca. Brian Yang and Dexter Yan invite guest speaker Liu Liu to discuss reasons behind the particularly active deal-making scene in the China biotech sector. https://scrip.citeline.com/SC149598/Chinese-Language-Podcast--AZMN...

In this edition of Cardio Conversations, Medtech Insight editor Reed Miller talked to Robert Chisena, the co-founder and CTO of AVS. He talked about the company's novel interventional technology for calcified peripheral arterial disease and how the company came together during the pandemic. Further Reading https://medtech.citeline.com/MT148128/Shockwave-Begins-First-All-Female-Study-Of-Coronary-In...

Pink Sheet reporter and editors discuss key US and EU legislation that impacted 2023 and how it also could affect 2024, including EU legislative reform (:56), US Medicare drug price negotiations (14:43), and the US Food and Drug Administration user fee reauthorization (30:57). More On These Topics From The Pink Sheet European Commission Explains Impact Of EU Pharma Review On SMEs & Non-Profit Enti...

Join us for an insightful Q&A session with Dr. Vega, where we delve into the groundbreaking world of Multi-Cancer Early Detection (MCED) and the future of cancer detection.

In this episode, In Vivo speaks to Bruce Leuchter, CEO of Neurvati Neurosciences, about ways clinical drug development in rare neurologic diseases is being held back and what can be done to make the process more efficient and successful.

世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。  今回取り上げた記事はこちら  「Clinical Trial Diversity Plans: Early Oncology Experience Shows More Work Needed, US FDA Says（邦題意訳：FDA、被験者の多様性を義務化へ　がん治験では課題も）」  https://pink.citel...

In this episode, Medtech Insight regulatory reporter Hannah Daniel speaks to King & Spalding’s Eric Henry about the year’s most influential digital health regulations in the US and EU, and what we may have missed in all the excitement.

In this podcast Scrip looks at the some upcoming clinical catalysts for biopharma, judged by the size of the sales forecasts at stake. Companies including Sanofi, Cytokinetics, Corcept and Inventiva stand to gain – or lose.

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: first ever gene editing FDA nod; US FTC ruffles pharma’s feathers; AstraZeneca pays to play in RSV; Syndax leukemia drug makes splash at ASH; BMS bets big on Chinese ADC. https://scrip.citeline.com/SC149527/Quick-Listen-Scrips-Five-MustKnow-Things

Pink Sheet reporters and editors in the US and Europe consider the growth and impact of Project Orbis after a year in which two major regulators joined the program, but several countries did not keep up with the US approval pace. More On These Topics From The Pink Sheet Project Orbis 2023: FDA Approves Six New Cancer Drugs, But Partner Nations Lag Behind: https://pink.citeline.com/PS149452/Project...

Brian Yang and Dexter Yan discuss Biokin/BMS's ADC deal, WuXi Biologics' share price drop, BlissBio's recent developments and Pfizer's divestment of Prevenar 13 commercial rights in China to a Chinese local partner. https://scrip.citeline.com/SC149497/Chinese-Language-Podcast-BiokinBMS-Deal-Developments-At-Pfizer-BlissBio-WuXi-Biologics

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: another acquisition for AbbVie; Roche buys into the obesity market; J&J’s oral immunology push; oral incretins advance; and AstraZeneca on Chinese innovation. https://scrip.citeline.com/SC149480/Quick-Listen-Scrips-Five-MustKnow-Things

In this episode, HBW Insight speaks to Aurélie Perrichet, regional director, Europe at the International Fragrance Association. We discussed the implications of planned revisions to the European Commission’s Classification, Labeling and Packaging (CLP) regulation, which may re-categorize biological materials as mixtures, from their current status as substances. Perrichet also speculated how the pr...

최근 제프리스 헬스케어 컨퍼런스에서 발표된 제약바이오산업의 생성형인공지능 적용사례에 대한 Scrip 기사를 요약한 내용입니다. https://scrip.citeline.com/SC149412/As-Biopharma-Adopts-Generative-AI-The-People-Element-Is-Crucial-To-Success

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: CAR-Ts and malignancies; comeback for GSK’s Blenrep?; Novartis’s pipeline cull; FGF21 analogs in NASH; and a call to action from the Scrip Awards Lifetime Achievement winner. https://scrip.citeline.com/SC149443/Quick-Listen-Scrips-Five-MustKnow-Things

Pink Sheet reporter and editors discuss the FDA acknowledging reports of malignancies in patients who received CAR-T cell immunotherapies (:35), the agency’s policy for using background music in direct-to-consumer advertising (7:27), and the FDA’s new incoming principal deputy commissioner (13:44). More On These Topics From The Pink Sheet CAR-T Malignancy Reports Could Temper Excitement For Use Be...

In this podcast, In Vivo speaks to Sara Barrington, CEO of Verici DX. During the discussion, Barrington outlines the current challenges facing patients post-transplant, why current diagnostics are inadequate, and where the overall transplant market is headed, considering the rise of home dialysis and the potential future for xenotransplants.

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Bayer’s Phase III failure; US group seeks Japan changes; AstraZeneca winning AKT race for now; NASH developments at AASLD; and the Q3 impact of China’s corruption campaign. https://scrip.citeline.com/SC149413/Quick-Listen-Scrips-Five-MustKnow-Things

Datamonitor Healthcare’s Epidemiology team (Ridwaan Ibrahim, Lucia Rodriguez-Garcia, Maya Trivedy, and Asma Ali) discuss the current trends in epidemiology throughout the world, and how epidemiology data is being used to support drug discovery and improve health outcomes. Topics discussed include epidemiology methodologies, Alzheimer’s Disease, non-communicable diseases in Africa, genetic epidemio...